Omidenepag Isopropyl 0.002% · ophthalmic solution
Antiglaucoma
Approved uses
Open-angle glaucoma or ocular hypertension
One drop in the affected eye(s) once daily in the evening
An EP2 agonist, not an FP prostaglandin, so it is an option when a conventional prostaglandin is not tolerated
Contraindications
None.
Omidenepag isopropyl 0.002% (0.02 mg/mL) ophthalmic solution, 2.5 mL in a 5 mL bottle; package of 1 bottle or multi-pack of 3 bottles
Omidenepag is a relatively selective EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown at this time.
Warnings & Precautions
- Pigmentation: Pigmentation is expected to increase as long as omidenepag isopropyl ophthalmic solution is administered. After discontinuation, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes are likely to be reversible in most patients. Treatment can be continued in patients who develop noticeably increased iris pigmentation, but these patients should be examined regularly.
- Eyelash changes: Omlonti may gradually change eyelashes and vellus hair in the treated eye, including increased length, thickness, and the number of lashes or hairs. Eyelash changes are usually reversible upon discontinuation of treatment.
- Ocular inflammation: Ocular inflammation has been reported in patients taking Omlonti. Use with caution in patients with active ocular inflammation, including iritis/uveitis.
- Macular edema: Macular edema, including cystoid macular edema, has been reported during clinical trials in patients with pseudophakia receiving Omlonti. Use with caution in aphakic patients, in pseudophakic patients, or in patients with known risk factors for macular edema.
- Risk of contamination and potential injury to the eye: Advise patients to avoid touching the tip of the bottle to the eye or any surface, as this may contaminate the solution, and to not touch the tip to their eye to avoid the potential for injury to the eye.
Common Side Effects
The most common adverse reactions with incidence ≥ 1% are conjunctival hyperemia (9%), photophobia (5%), vision blurred (4%), dry eye (3%), instillation site pain (3%), eye pain (2%), ocular hyperemia (2%), punctate keratitis (2%), headache (2%), eye irritation (1%), and visual impairment (1%).
Pregnancy: There are no available data on the use of Omlonti in pregnant women. In pregnant rabbits, subcutaneous omidenepag isopropyl throughout organogenesis produced fetal skeletal anomalies at 24 times the clinical dose, based on estimated plasma C max. Omidenepag isopropyl was not teratogenic in rats when given subcutaneously at 2,452 times the clinical dose, based on estimated plasma C max.
Lactation: There are no data on the presence of Omlonti in human milk, the effects on the breastfed infant, or the effects on milk production. Systemic exposure to omidenepag after topical ocular administration is low, and it is not known whether measurable levels of omidenepag would be present in maternal milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Omlonti and any unknown potential adverse effects on the breast-fed child from Omlonti.
Safety and effectiveness have not been established in pediatric patients.